Any current/future new fundraising through debt or equity?

Currently, Bodal Chemicals is not targeting any major capex for the next couple of years, focusing instead on consolidating the current setup and improving utilization. Small debottlenecking or minor brownfield expansions may occur, but nothing major requiring significant fundraising. The company is actively aiming to reduce existing term debt by INR150-175 crores by the end of the current year through scheduled repayments and asset sales. Targeted debt-to-EBITDA ratio is near 2.5; only after achieving this leverage profile will the company consider next growth plans. There is no expli

Any current/future capex/capital investment/strategic investment?

No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup. Small debottlenecking or Brownfield expansions may happen but will be very limited in scale. Strategic land sale of about 8 acres at Rajpura to a large chlorine consumer to develop pipeline chlorine buyers, not a real estate deal but a business collaboration. The company has about 62 acres of surplus land for future expansions, ensuring capacity for growth over the next 10-15 years. Future growth capex will be considered after achieving a targeted debt-to-EBITDA ratio near 2.

Future growth expectations in sales/revenue/volumes?

Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently. Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment. Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months. Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26. TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4. Focusing on consolidating existing businesses with limited capex for next 2-

Future growth expectations in earnings/operating earnings/profits/EPS?

Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%. EBITDA margin guidance is around 11% to 12%, corresponding to an operating income of about INR35 crores per quarter. Net profit expected approx. INR70 to 80 crores for next year, implying 7% to 8% return on investment (ROI). Two key businesses — benzene derivatives and TCCA — are expected to scale up in 3-6 months, contributing positively to margins and profitability. Benzene business revenue expected to reach INR100 crores in FY26, potentially INR300 crores at full capacity next year

IN US

Sale is live|00:00:00left today

Bodal Chemicals LtdQ2 FY25Chemicals & Petrochemicals

Bodal Chemicals Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹66.3P/E: 30.4Market Cap: ₹921 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Company targets to reach INR2,000-2,100 crores revenue in FY27, up from about INR1,900 crores currently.
→Expecting 12%-13% EBITDA margin leading to INR70-80 crores net profit and 7%-8% return on investment.
→Growth expected from ramp-up in benzene derivatives and TCCA business volumes in next 3-6 months.
→Benzene derivatives currently at 20%-30% utilization, targeting 70%-80% utilization by Q3/Q4 FY26.
→TCCA market share expected to improve post-import duty clarity, with production resuming as inventory reduces by Q3/Q4.
→Focusing on consolidating existing businesses with limited capex for next 2-3 years, mainly small debottlenecking.
→Target to raise caustic soda capacity utilization to 90%-95% in coming quarters.
→Export contributes ~22% of revenue; U.S. export negligible (~1%).

Margin guidance

Category 2

→Company targets revenue of around INR1,900 crores for FY26, with a potential upside or downside of 5%.
→EBITDA margin guidance is around 11% to 12%, corresponding to an operating income of about INR35 crores per quarter.
→Net profit expected approx. INR70 to 80 crores for next year, implying 7% to 8% return on investment (ROI).
→Two key businesses — benzene derivatives and TCCA — are expected to scale up in 3-6 months, contributing positively to margins and profitability.
→Benzene business revenue expected to reach INR100 crores in FY26, potentially INR300 crores at full capacity next year.
→Capacity utilization targets for chlor-alkali near 90-95% within a few quarters.
→Improved pricing in TCCA anticipated by Q3/Q4 post import duty impact, helping margins further.
→Debt reduction plan ongoing, targeting reduction of INR150-175 crores term debt by year-end, aiding financial health.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, Bodal Chemicals is not targeting any major capex for the next couple of years, focusing instead on consolidating the current setup and improving utilization.
→Small debottlenecking or minor brownfield expansions may occur, but nothing major requiring significant fundraising.
→The company is actively aiming to reduce existing term debt by INR150-175 crores by the end of the current year through scheduled repayments and asset sales.
→Targeted debt-to-EBITDA ratio is near 2.5; only after achieving this leverage profile will the company consider next growth plans.
→There is no explicit mention of new equity fundraising in the transcript.
→The focus is on improving profitability and reducing debt before planning any new fundraising for expansion.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Bodal Chemicals Limited. However, some relevant insights include: - TCCA production was paused due to inventory build-up but is expected to resume with clarity in future demand, likely by Q3 or Q4 of FY26. - Benzene derivatives business is ramping up, with utilization expected to reach 70-80% by Q4 FY26, indicating growing orders. - Dye Intermediates and Dyestuff divisions are maintaining volume and revenue levels with some challenges in raw material prices. - The company expects growth in turnover to INR1,900-2,100 crores in FY26, supported by existing business and new projects. - No specific figures on order book or pending orders were disclosed during the call.

Capex plans

→No major capex planned in the next couple of years; focus is on consolidating and optimizing the current setup.
→Small debottlenecking or Brownfield expansions may happen but will be very limited in scale.
→Strategic land sale of about 8 acres at Rajpura to a large chlorine consumer to develop pipeline chlorine buyers, not a real estate deal but a business collaboration.
→The company has about 62 acres of surplus land for future expansions, ensuring capacity for growth over the next 10-15 years.
→Future growth capex will be considered after achieving a targeted debt-to-EBITDA ratio near 2.5, indicating focus on debt reduction before new investments.
→Emphasis on increasing capacity utilization and improving leverage profile before undertaking major capital investments.

How does Bodal Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Bodal Chemicals Ltd

Rev 3Mar 2

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Bodal Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio